Quintiles Reaches New Milestone in Social Health

MediGuard.org reaches 2.5 million members

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Quintiles today announced that its online social community at www.MediGuard.org has reached 2.5 million members in just three years.

MediGuard members can actively manage their personal health and safety in regards to drug-drug and drug-disease interactions. It is a free and secure source of information for registered users who want to get informed, stay informed and share feedback about their medications. MediGuard.org has received vital support from patient advocacy groups and offers balanced and timely information to help patients manage their healthcare for themselves or loved ones.

Today, MediGuard.org is the largest single community of highly engaged, medically and demographically profiled patients who have consented to share personal health information. Initially launched as iGuard.org in the United States, the community name has now changed to MediGuard.org and local adaptations of the site are now available in the United Kingdom, Spain, France, Germany, and Australia.

“Three years ago Quintiles knew mobilizing patients would be essential in the New Health, but we had no idea patients would be so enthusiastic,” said John Ratliff, Quintiles President and Chief Operating Officer. “Having access to such an engaged, clinically profiled pool of patients is helping Quintiles design better, faster clinical trials; increase drug safety and comparative effectiveness research through faster observational studies, and even make research into genetic predictors of treatment success possible today.”

In addition to MediGuard.org, Quintiles recently launched ClinicalResearch.com to raise awareness, understanding and participation in clinical research. The site’s easy-to-use search tool enables site visitors to access the most complete list of trials around the globe and to locate relevant studies with only a postal code and condition of interest. Its more than 150,000 members are proactively notified of study opportunities in their area as they become available.

Both MediGuard.org and ClinicalResearch.com were recently honored by the Web Health Awards for empowering patients to make better informed health decisions.

About Quintiles

Quintiles is the only fully integrated bio pharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.



CONTACT:

Quintiles
Jay Johnson, 919-998-2000, Media Relations
[email protected] or
Greg Connors, 919-998-2000, Investor Relations
[email protected]

KEYWORDS:   Australia  United Kingdom  United States  Europe  Asia Pacific  North America  Australia/Oceania  France  Germany  North Carolina  Spain

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Pharmaceutical  Social Media  Communications

MEDIA:

Logo
 Logo

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.